Why Freenome, Inc.’s (FRNM) Stock Is Up 6.31%
As of Friday, August 28, Freenome, Inc.’s FRNM share price has surged by 6.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Freenome, Inc.’s (FRNM) Stock Is Up 5.32%
As of Monday, August 17, Freenome, Inc.’s FRNM share price has surged by 5.32%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Freenome, Inc.’s (FRNM) Stock Is Up 5.56%
As of Monday, August 10, Freenome, Inc.’s FRNM share price has surged by 5.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is Freenome, Inc. (FRNM) Stock a Good Investment?
Learn more about Freenome, Inc.'s (FRNM) stock grades for Momentum and determine whether this Biotechnology stock meets your investment needs.Rosalio Madrigal
Financial Summary
| Share Statistics | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,752.5 | $282.4 | 52% |
|
| Shares Out (Mil) | 26.7 | 54.0 | 35% |
|
| Institutional Ownership | 51.2% | 93.1% | 36% |
|
| Float (Mil) | 68.8 | 42.2 | 54% |
|
| Beta | 0.35 | 0.94 | 20% |
|
| Avg Daily Volume (000s) | 876 | 482 | 70% |
|
| Price Change (52-week) |
57.3% | 59.9% | 83% |
|
| Growth | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($235) | ($43) | 6% |
|
| EPS (TTM) | ($8.836) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($108) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $29 | $2 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $300 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $3,057 | $190 | 54% |
|
| Valuation | FRNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (494.8%) | 66.9% | 0% |
|
| Net Margin | (664.6%) | (74.2%) | 1% |
|
| ROA | (118.1%) | (47.7%) | 5% |
|
| ROE | 19.2% | (55.0%) | 78% |
|
| Liabilities to Assets | 106.7% | 29.8% | 95% |
|
| F-Score | 1 | 3 | na |
|
Freenome, Inc. did not pass any screens on 9/4/2026.
